UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

This is an exploratory, open-label, investigator-initiated trial (IIT) of the safety, efficacy, and PK/Pd of UB-VV400 alone and in combination with rapamycin in adult subjects with R/R LBCL. LBCL will include subjects with aggressive lymphoma, defined as diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), including high-grade lymphoma (HGL) with double/triple hit DLBCL; transformed DLBCL (tDLBCL), including Richter's transformation; follicular lymphoma Grade 3B (FL3B); and primary mediastinal B-cell lymphoma (PMBCL). The study will include subjects who have had prior CD19-dire

Trial Details

NCT ID

NCT06743503

Phase

PHASE1

Sponsor

Nanjing IASO Biotechnology Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

UB-VV400
Rapamycin

Locations (sample)

Nanjing, China|32.06167,118.77778
Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

Age ≥ 18 at time of consent.
Provide voluntary written informed consent.
Relapsed/refractory disease for subjects that are either CAR T-naive or CAR T-exposed.
Measurable disease according to Lugano 2014 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →